AlloCAR T™ SEE OUR AlloCAR T™ PLATFORM ALLOGENEIC CAR T -THE NEXT REVOLUTION IN CELL THERAPY Allogene is working to overcome the limitations of autologous CAR T therapies by creating investigational allogeneic…
NEWS CENTER LEARN ABOUT AlloCAR T™ LATEST PRESS RELEASES Apr 26, 2024 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T…
NEWS CENTER LEARN ABOUT AlloCAR T™ PRODUCTS LATEST PRESS RELEASES Apr 26, 2024 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR…
SCIENCE LEARN ABOUT OUR PIPELINE REDEFINING THE FUTURE OF CAR T Allogene is working to overcome the limitations of autologous CAR T therapies by creating investigational allogeneic CAR T cell products,…
ALPHA3 PIVOTAL PHASE 2 ALPHA3 TRIAL INITIATED Allogene initiates the industry's first pivotal first line (1L) consolidation trial of an investigational allogeneic CAR T in LBCL CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IS…
ALPHA3 PIVOTAL PHASE 2 ALPHA3 TRIAL INITIATED Allogene initiates the industry's first pivotal first line (1L) consolidation trial of an investigational allogeneic CAR T in LBCL CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IS…
CAREERS At Allogene, you'll find an experienced, high-performing team of employees whose sole focus is to transform the treatment of cancer and autoimmune disease. Our deep pipeline of innovative AlloCAR…
REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PRODUCT PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >>…